Detalles de la búsqueda
1.
Trends in health care spending on kidney cancer in the United States, 1996-2016.
Cancer;
129(14): 2161-2168, 2023 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37005866
2.
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist;
28(9): 812-822, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37011230
3.
Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030).
Gastroenterology;
162(4): 1098-1110.e2, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34922947
4.
Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016.
Am J Gastroenterol;
116(10): 2060-2067, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33998785
5.
Population-based Trends in Healthcare Utilization and National Healthcare Spending on Pancreatitis in North America.
Gastroenterology;
161(5): 1698-1701.e5, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34419461
6.
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
JAMA Netw Open;
7(1): e2352302, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236598
7.
Diffuse Jejunal Lipomatosis and Associated Complications.
ACG Case Rep J;
10(10): e01179, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37860810
8.
Age-related disparities and trends in national healthcare spending for management of appendicitis in the United States: A retrospective cost-analysis.
Surgery;
173(4): 896-903, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642654
9.
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
JAMA Netw Open;
6(6): e2319607, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37351883
10.
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Curr Oncol;
30(10): 8936-8947, 2023 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37887546
11.
Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.
Curr Oncol;
30(12): 10396-10407, 2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38132391
12.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep;
4(4): 100482, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37090101
13.
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Clin Lung Cancer;
24(3): e152-e159, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774234
14.
Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab.
Curr Oncol;
29(10): 7695-7704, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36290885
15.
Medications and dosages used in medical assistance in dying: a cross-sectional study.
CMAJ Open;
10(1): E19-E26, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042691
16.
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
JAMA Netw Open;
5(12): e2245596, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36480204
17.
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Cancer Med;
10(8): 2618-2626, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724676
18.
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.
Curr Oncol;
28(5): 4213-4222, 2021 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34677275
19.
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Eur J Cancer;
151: 115-125, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33975059
20.
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Clin Genitourin Cancer;
19(4): 354-361, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33863648